Keyphrases
Acute Ischemic Stroke
52%
Ischemic Stroke
35%
Transient Ischemic Attack
35%
Intracerebral Hemorrhage
32%
Post-stroke
26%
Cognitive Decline
24%
Stroke Patients
23%
Acute Stroke
22%
Endovascular Thrombectomy
21%
Stroke Ischemic
21%
Cerebral Venous Sinus Thrombosis
19%
Poor Outcome
18%
Tabasco
18%
National Institutes of Health Stroke Scale (NIHSS)
17%
Tel Aviv
17%
Modified Rankin Scale
16%
Stroke Survivors
15%
Intraventricular Hemorrhage
13%
Intravenous Tissue Plasminogen Activator
13%
Intracranial Hemorrhage
13%
Cerebral Microbleeds
12%
Subcortical Stroke
12%
Tissue Plasminogen Activator (t-PA)
12%
Post-stroke Cognitive Impairment
12%
Intra-arterial Therapy
12%
Pooled Analysis
11%
Prospective Cohort Study
11%
Thrombolysis
11%
C-C Chemokine Receptor Type 5 (CCR5)
11%
Cognitive Impairment
11%
Small Vessel Disease
9%
Confidence Interval
9%
Hemorrhagic Transformation
9%
Individual Patient Data
8%
Clinical Outcomes
8%
First-ever
8%
Anterior Circulation
8%
Cognitive Score
8%
Stroke Risk
8%
Antithrombotic Therapy
8%
Large Vessel Occlusion
7%
Stroke Progression
7%
Symptom Onset
7%
Protective Factors
7%
Cognitive State
7%
Maraviroc
7%
Cardioembolic Stroke
7%
Cocaine
7%
Hippocampal Volume
7%
At Discharge
7%
Medicine and Dentistry
Apoplexy
100%
Brain Ischemia
65%
Cerebral Hemorrhage
36%
Transient Ischemic Attack
21%
Cohort Analysis
21%
Blood Clot Lysis
19%
Cerebral Sinus Thrombosis
19%
Percutaneous Thrombectomy
17%
Tissue Plasminogen Activator
16%
National Institutes of Health Stroke Scale
15%
Infarction
13%
Cognitive Defect
12%
Intraarterial Drug Administration
11%
Large Vessel Occlusion
9%
Recanalization
9%
Patient-Data
8%
Pooled Analysis
8%
Time to Treatment
7%
Maraviroc
7%
Protective Factor
7%
Depressive Disorder
7%
Antithrombotic
6%
Biological Marker
6%
Antiplatelet
5%
Bleeding
5%
Clinical Trial
5%
Cancer
5%
Placebo
5%
Modified Rankin Scale
5%
Magnetic Resonance Imaging
5%
Collateral Circulation
5%